ITGAX and serous adenocarcinoma: Magalhaes et al. conducted an immunohistochemical analysis and demonstrated that MSLN expression in patients with advanced serous carcinomas did not predict the clinical outcome but was correlated with CD11c+-positive immune infiltrate in neoplasms.